Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in CIDP (CIDPRIT)
NCT06325943Phase 3Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Apr 2019
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Humanitas Research Hospital. Started Apr 2019; status: completed.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06325943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325943.